JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v4i3.2343 jpsim.v4i3.2343 Review Article Role of Combination of Sacubitril and Valsartan for Management of Patients with Decompensated Heart Failure Ahmad Waqar doc_waqar10@yahoo.com * Sajjad Anas Abbas Farwa Riaz Amna Shehzad Rae Hasnain Waheed Iqra Department of Cardiology, Mayo Hospital, Lahore *Correspondence: Waqar Ahmad (doc_waqar10@yahoo.com) 25 09 2023 2023 4 3 214 217 03 06 2023 20 07 2023 Copyright © 2023 The Author(s) 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To determine the outcome of sacubitril plus valsartan in patients with decompensated heart failure

 Methodology

This quasi experimental study was done at Department of Cardiology, Mayo Hospital, Lahore during March 2022 to March 2023. Total 200 patients with decompensated heart failure were enrolled through emergency and admitted in cardiology wards. All patients were given Sacubitril / valsartan (200 mg, twice daily) during hospital stay. Then all patients were followed-up until discharge from the hospital. If patient died during hospital stay, then mortality was noted. data was colelcted in proforma whiel analysed in SPSS version 25.

 Results

In this trial, we enrolled total 200 individuals with decompensated heart failure with mean age of 55.02 ± 8.64 years. Out of 200 individuals, 111 (55.5%) were males and 89 (44.5%) were females. Out of 200 individuals, 34 (17.0%) individuals died during follow-up in the hospital after receiving sacubitril with valsartan combination drug. For ejection fraction, the mortality was significantly higher in individuals who had ejection fraction less than 22% (27.9%) as compared to individuals with ejection fraction was higher than 22% (3.4%, p-value < 0.05).

 Conclusion

The outcome of sacubitril with valsartan combination drug is better and morality is less.

 Keywords in-hospital mortality sacubitril valsartan decompensated heart failure References Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603. Orso F, Fabbri G, Maggioni AP. Epidemiology of Heart Failure. Handbook of experimental pharmacology. 2017;243:15-33. Mangini S, Pires PV, Braga FG, Bacal F. Decompensated heart failure. Einstein (Sao Paulo, Brazil). 2013;11(3):383-91. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Failure. 2016;9(3):e002744. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Cur Heart Failure Rep. 2014;11(4):404-15. Haddad P, McKelvie RS. Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions. Value Health. 2017;20(9):A605. Afonso-Silva M, Laires PA. PCV6 - Sacubitril/valsartan in heart failure: projected health outcomes in Portugal. Value Health. 2018;21(S-1):S93. Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. Circ Heart Failure. 2018;11(2):e004302. Lewis EF, Claggett B, Solomon SD, McMurray JJV, Swedberg K, Desai AS, et al. Racial Differences, Outcomes and Response to Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: PARADIGM-HF. J Card Failure. 2016;22(8):S9-S10. Novartis. Sacubitril/valsartan for chronic heart failure. Aus Prescriber. 2016;39(6):226-7. Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Therap Adv Chronic Dis. 2016;7(6):278-90. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatolian J cardiol. 2015;15(1):63-8. Lombardi C, Peveri G, Cani D, Latta F, Bonelli A, Tomasoni D, et al. In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Failure. 2020;7(5):2650-61. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958-68. Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022;108(17):1351-60. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). European J Heart Failure. 2013;15(9):1062-73. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New Eng J Med. 2014;371(11):993-1004. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JG, Greene SJ, O'Connor CM, et al. The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. Eu J Heart Failure. 2018;20(6):963-72. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285-8. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. New Eng J Med. 2019;380(6):539-48. Wang C-C, Wu C-K, Tsai M-L, Lee C-M, Huang W-C, Chou H-H, et al. 2019 focused update of the guidelines of the Taiwan society of cardiology for the diagnosis and treatment of heart failure. Acta Cardiologica Sinica. 2019;35(3):244. Wang C-C, Chang H-Y, Yin W-H, Wu Y-W, Chu P-H, Wu C-C, et al. TSOC-HFrEF registry: a registry of hospitalized patients with decompensated systolic heart failure: description of population and management. Acta Cardiologica Sinica. 2016;32(4):400. Woo KS, Nicholls M. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharm. 1995;40(2):141.